-
Pfizer, BioNTech Covid-19 Vaccine 90% Effective in Interim Analysis of Phase 3 Trial, Companies Say
Pfizer/BioNTech: Experimental Vaccine Found To Be Over 90% Effective In Preventing Covid-19
— LiveSquawk (@LiveSquawk) November 9, 2020
-
Pfizer/BioNTech: Plans To Seek US Emergency Use Authorization Soon After Safety Milestone Is Reached In Late November
— LiveSquawk (@LiveSquawk) November 9, 2020
-Expects Trial Will Reach Final Analysis Point Of 164 Infections By First Or Second Week Of December
-
Covid-19 vaccine from Pfizer and BioNTech is strongly effective, early data from large trial indicate
Pfizer and partner BioNTech said Monday that their vaccine against Covid-19 was strongly effective, exceeding expectations with results that are likely to be met with cautious excitement — and relief — in the face of the global pandemic. The vaccine is the first to be tested in the United States to generate late-stage data. The companies said an early analysis of the results showed that individuals who received two injections of the vaccine three weeks apart experienced more than 90% fewer cases of symptomatic Covid-19 than those who received a placebo. For months, researchers have cautioned that a vaccine that ... (full story)
- Comments / Top
- Subscribe